The effect of early treatment with ivermectin on viral load, symptoms and humoral response in patients with non-severe COVID-19: A pilot, double-blind, placebo-controlled, randomized clinical trial
More News: Ivermectin is effectively a “miracle drug” against COVID-19
As of December 21, 2020, there have been over 70 million cases and 1·6 million COVID-19 deaths worldwide. Although the threshold is difficult to predict accurately, the spread of SARS-CoV-2 is unlikely to stop before at least 50% of the population has gained immunity, either by vaccination or recovering from a naturally-acquired infection.
There are now promising vaccines candidates advancing to emergency regulatory approval, but there is a projected delay in global access to the level required for population impact on the trajectory of the pandemic. While efforts are ongoing to develop treatment options, relatively less attention has been devoted to evaluating drug-based transmission blocking or transmission reduction strategies.
These strategies would consist in administering a drug with the aim of reducing onward transmission by those infected and could serve to reduce the burden on health system and gain time until vaccines are fully tested and scaled-up.Ivermectin is a widely used antiparasitic drug with known partial efficacy against several single-strain RNA viruses. Caly et al. reported in vitro inhibition of SARS-CoV-2 replication using micromolar concentrations of ivermectin.
These findings, together with early observational evidence and ecological evidence, prompted several Latin-American countries to include ivermectin as part of the national policy for COVID-19 treatment.As of December 21, 2020, there are 45 studies evaluating the efficacy of ivermectin to treat or prevent COVID-19 registered in clinicaltrials.gov, and 74 trials registered in WHO´s International Clinical Trials Registry Platform (https://apps.who.int/trialsearch/) of which at least 14 are already completed.
Although some observational and case control studies as well as emerging small randomized clinical trials suggest a potential utility. Yet, there is still a dearth of robust, randomized controlled trials to appropriately inform policy decisions.This trial was designed as a pilot to evaluate whether the maximum approved dose of ivermectin in Europe could have an impact on the transmission of SARS-CoV-2 when administered early after disease onset.treatment-with-ivermectin
more info: thelancet